Compass Therapeutics (CMPX) Shares Outstanding (2018 - 2026)

Compass Therapeutics has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $180.1 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 30.23% year-over-year to $180.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180.1 million (up 30.23% YoY) and the FY2025 annual result came in at $178.3 million, up 29.39% from the prior year.
• Shares Outstanding (Entity) climbed to $180.1 million in Q1 2026 per CMPX's latest filing, from $178.3 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $180.1 million in Q1 2026 and troughed at $100.9 million in Q1 2022.
• A 5-year average of $134.1 million and a median of $137.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) jumped 96.65% in 2022, then rose 0.5% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $105.2 million in 2022, then gained by 21.37% to $127.7 million in 2023, then gained by 7.95% to $137.8 million in 2024, then increased by 29.39% to $178.3 million in 2025, then climbed by 0.99% to $180.1 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $180.1 million, $178.3 million, and $177.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.